Daxor Corp (DXR): Quarterly Revenue Growth

Public company logo of Daxor Corp. (DXR)

Daxor Corporation is recognized as the gold standard in blood volume determination, maintaining an impeccable reputation among intensivists. The quarterly revenue trend illustrates this status, with -93.50 serving as the current metric. Revenues are based on global supplies to cardiology and science, while the stability of the B2B segment is ensured by the implementation of BVA-100 systems and FDA-controlled consumables.

DXR (Daxor Corporation) Quarterly Revenue Growth history from 07/04/2022 to 11/20/2026

Analytical breakdowns for Daxor Corp. (DXR)

- stock price and consensus target price:
- money and cash flow information:
Basic company analysis:DXR - Daxor Corp
Flagship merchandise of Daxor Corp

Quarterly revenue growth measures the pace of capital inflow, allowing for the identification of fundamental imbalances and the risk of a correction should sales expansion slow while share prices rise. By analyzing the quarterly sales dynamics on GURU.Markets, an investor can assess the scaling efficiency of Daxor Corporation (DXR) within a conservative medical market, where the uniqueness of its blood measurement method ensures a steady but slow increase in the customer base.